Cellares, a life sciences technology company that automates cell therapy manufacturing, has secured $82 million in a Series B round, bringing total funding to date to $100 million.

The round was led by new investor Decheng Capital and co-led by existing investor Eclipse Ventures. Skyviews Life Science joined as a new investor, with previous investor 8VC also participating.

Cellares is developing a solution to overcome the limitations associated with manufacturing cell therapies to make them more affordable and widely available to patients in need.